Pharmacological properties of MM-706, a new prostacyclin derivative.

@article{Ragazzi1995PharmacologicalPO,
  title={Pharmacological properties of MM-706, a new prostacyclin derivative.},
  author={Eugenio Ragazzi and Alessandro Chinellato and U. Lille and Margus Lopp and Maria Gabriella Doni and Giuliana Fassina},
  journal={General pharmacology},
  year={1995},
  volume={26 4},
  pages={
          703-9
        }
}
Inhibition of platelet activation by MM-706, a stable carbacyclin analog, in the conscious rat.
Neuronal prostacyclin receptors.
  • H. Wise
  • Biology, Medicine
    Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques
  • 1997
TLDR
It is hoped that this review of recent developments in the study of neuronal prostacyclin receptors will set the scene for what is a rapidly developing and exciting area of research.
PROSTANOID ACTION ON THE HUMAN PULMONARY VASCULAR SYSTEM
TLDR
Four types of prostanoid receptor are present on pulmonary arterial vessels of man and mediate constriction, the agonist potency ranking being SC 46275 > sulprostone > misoprostol≥PGE2; this action needs to be borne in mind when PGE analogues are used therapeutically.
Thromboxane A2 and Other Eicosanoids
TLDR
This chapter will provide a brief discussion of alterations in platelet TXA2 receptors in disease states and focus on discoveries made since Arita et al. (1989).

References

SHOWING 1-10 OF 27 REFERENCES
Pharmacokinetics and Platelet Antiaggregating Effects of Beraprost, an Oral Stable Prostacyclin Analogue, in Healthy Volunteers
TLDR
Data indicate that orally active prostacyclin BPS (40 or 60 μg) exerts its maximal antiaggregating effects between 0.5 and 1 h, and that some subjects complained of moderate postdrug absorption headaches and flushes.
Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures.
TLDR
Iloprost provides a pharmacotherapeutic option for patients with severe peripheral vascular disease, a condition for which few alternative drug therapies exist and its potent but short-lived effects make it well-suited to certain therapeutic niches such as the management of intraoperative platelet activation.
...
...